Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial. Please see the links below for current open trials at UC San Francisco.
CC#187015: A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Marissa Gin (415) 476-3816: [email protected]
CC#214514: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Contact: Marin Pollak (415) 476-7974: [email protected]
CC#214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Bryan Le (415) 502-6313: [email protected]
Not currently enrolling
CC#22705: A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Contact: Cate Gwinn: [email protected]
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Lauren Ford (415) 353-7284: [email protected]
CC#19721: Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients with Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Contact: Hewitt Chang (415) 514-1571: [email protected]
Colorectal Non-Therapeutic Studies
CC#134510: GIMP: Molecular Profiling in Gastrointestinal Malignancies
Contact: Dalila Stanfield (415) 476-2976: [email protected]
CC#204518: BESPOKE Study of ctDNA-Guided Therapy in Colorectal Cancer
Contact: Marin Pollak (415) 476-7974: [email protected]
CC#21456: Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors (Tools To Be Fit)
Contact: Evelyn Montenegro (415) 514-6258: [email protected]
https://toolstobefit.eurekaplatform.org/
CC#214519: Evaluation of a Pilot Integrated Rectal Cancer Exercise Program (REP’s)
Contact: Banaz Shwan (415) 514-7285: [email protected]
CC#224512: The Optimization of Adaptive Text Messages to Improve Nutrition for Cancer Survivors (OATS)
Contact: Evelyn Montenegro (415) 514-6258: [email protected]
CC#20958: A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination with Dabrafenib for the treatment of Advanced Solid Tumors with MAPK Pathway Mutations
Contact: Shivani Doshi, [email protected]
AMC095: A Phase 1 Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Suzannah Henderson, [email protected]
CC#19958: First-In-Human, Open-Label, Phase I Dose Escalation and Cohort Expansion Study of BB-1701 in Locally Advanced/Metastatic Her2 Expressing Solid Tumors
Contact: Shivani Doshi, [email protected]
CC#21951: LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-Randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients with an Advanced Solid Tumor
Contact: Suzannah Henderson, [email protected]
Not currently enrolling
CC#199511: A Phase 1/2 Study of CYT-0851 (a RAD51 inhibitor) in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Contact: Anoushka Sharma, [email protected]
CC#209511: A first in human study of highly selective FGFR2 inhibitor, RLY-4008 in patients with intrahepatic cholangiocarcinoma (ICC)
Contact: Sukjun (James) Lee, [email protected]
CC#189515: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)
Contact: Shivani Doshi, [email protected]
CC#21953: A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Contact: Michelle Howell, [email protected]
Not currently enrolling
CC#21956: A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors
Contact: Christian Kelly, [email protected]
CC#21952: A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation
Contact: Suzannah Henderson, [email protected]
CC#209515: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
Contact: Kristy Tjokro, [email protected]
CC#21958: A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (PETRA)
Contact: Saoirse McCormack, [email protected]
Not currently enrolling
CC#21957: A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Contact: Kristy Tjokro, [email protected]
CC#189510: Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Contact: Suzannah Henderson, [email protected]
CC#209518: A Phase 1, Open-Label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety and Tolerability Study of PF 07265807 in Participants with Selected Advanced or Metastatic Solid Tumor Malignancies
Contact: Suzannah Henderson, [email protected]
CC#217013: A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
CC#217015: Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Contact: Saba Saidi: [email protected]
CC#21704: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Contact: Marissa Gin (415) 476-3816: [email protected]
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Lauren Ford (415) 353-7284: [email protected]
CC#19721: Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients with Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Contact: Hewitt Chang (415) 514-1571: [email protected]
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Bryan Le (415) 502-6313: [email protected]
CC#197010: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients with Advanced Mesothelin-Expressing Cancer
Contact: Saba Saidi: [email protected]
CC#204517: A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus-Liver)
Contact: Ashna Sethi (415) 353-1745: [email protected]
CC#194522: Phase II Trial of Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy
Contact: Luchia Andemicael (415) 476-8099: [email protected]
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Bryan Le (415) 502-6313: [email protected]
Not currently enrolling
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Lauren Ford (415) 353-7284: [email protected]
CC#19721: Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients with Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Contact: Hewitt Chang (415) 514-1571: [email protected]
Hepatocellular and Biliary Tract Non-Therapeutic Studies
CC#124512: Banking of Human Biological Specimens for Hepatobiliary Cancer Research Studies: UCSF Hepatobiliary Tissue Bank and Registry
Contact: Karen Zhang (415) 502-1877: [email protected]
CC#204516: A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Contact: Karen Zhang (415) 502-1877: [email protected]
CC#174535: A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma (HCC)
Contact: Karen Zhang (415) 502-1877: [email protected]
CC#187015: A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Marissa Gin (415) 476-3816: [email protected]
CC#17705: A Pilot Study of Pembrolizumab and Liver Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases.
Contact: Deneb Zavala (415) 514-7975: [email protected]
CC#197010: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Contact: Saba Saidi: [email protected]
CC#217013: A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
CC#22705: A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Contact: Cate Gwinn: [email protected]
CC#217015: Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Contact: Saba Saidi: [email protected]
CC#21705: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Contact: Deneb Zavala (415) 514-7975: [email protected]
CC#21708: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Contact: Saba Saidi: [email protected]
Not currently enrolling
CC#22703: A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
CC#21704: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Contact: Marissa Gin (415) 476-3816: [email protected]
CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases
Contact: Deneb Zavala (415) 514-7975: [email protected]
A021602: Randomized, Double-Blinded Phase III Study of Cabozantanib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Contact: Bryan Le (415) 502-6313: [email protected]
A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
Contact: Bryan Le (415) 502-6313: [email protected]
Neuroendocrine Tumors Non-Therapeutic Studies
CC#194520: e-NET: A Pilot Study Using a Web-Based Health Platform to Investigate Health-Related Quality of Life in Patients with Neuroendocrine Tumors
Contact: Farhana Moon: [email protected], [email protected]
https://enet.eurekaplatform.org/
CC#20456: Precision Promise Platform Trial For Metastatic Pancreatic Cancer
Contact: Nancy Kaushal (415) 514-7633: [email protected]
Not currently enrolling
A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Contact: Bryan Le (415) 502-6313: [email protected]
CC#214514: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Contact: Marin Pollak (415) 476-7974: [email protected]
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Bryan Le (415) 502-6313: [email protected]
Not currently enrolling
CC#217015: Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Contact: Saba Saidi: [email protected]
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Lauren Ford (415) 353-7284: [email protected]
Not Currently Enrolling
CC#19721: Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients with Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Contact: Hewitt Chang (415) 514-1571: [email protected]
Pancreatic Non-Therapeutic Studies
CC#134510: GIMP: Tissue GIMP & Blood GIMP (Collisson)
Contact: Lauren Ford (415) 353-7284: [email protected]
CC#184519: Cell Free DNA and Imaging in Advanced Gastrointestinal Cancers
Contact: Lauren Ford (415) 353-7284: [email protected]
CC#204513: Exploring the Role of the Intestinal Microbiome in Mediating Treatment Outcomes for Patients with Locally Advanced or Metastatic Pancreatic Cancer
Contact: Banaz Shwan (415) 514-7285: [email protected]
CC#214513: Navigating a Whole Genome vs. Panel Approach for Patients with Advanced Pancreatic Cancer
Contact: Lauren Ford (415) 353-7284: [email protected]
CC#214516: NABPLAGEM Pancreatic Cancer Registry Protocol
Contact: Dr. Erica Tsang: [email protected]
CC#21453: Demoralization and Depression in Pancreatic Cancer Patients
Contact: Sally Wu (415) 885-7740: [email protected]
CC#154520: Lifestyle and Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study (LOGIC)
Contact: Dalila Stanfield (415) 476-2976: [email protected]
CC#19801: Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer (NOONA)
Contact: Sally Wu (415) 885-7740: [email protected]
CC#21709: An Open Label Phase 1A/B Study of MTL-CEBPA in Combination with a PD-1 Inhibitor (PEMBROLIZUMAB) in Adult Patients with Advanced Solid Tumors (TIMEPOINT)
Contact: Carolyn Bridgman (415) 514-7975: [email protected]
CC#194521: Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/Paraganglioma
Contact: Paige Steiding (415) 514-6314: [email protected]
CC#214511: Electronic Patient Reported Outcomes in Patients with Gastrointestinal Cancers at Risk for Unplanned ED Visits and Hospitalizations
Contact: Param Kaur: [email protected]
CC#22457: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with actinium Ac 225 dotatate (RYZ101) to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior treatment with 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC) (ACTION-1)
Contact: Paige Steiding (415) 514-6314: [email protected]
CC#224514: A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy
Contact: Nancy Kaushal (415) 514-7633: [email protected]
CC#204520: A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish) - Part C
Contact: Alex Milloy (415) 502-3310: [email protected]
CC#20451: THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients with Advanced Pancreatic Cancer
Contact: Sally Wu (415) 885-7740: [email protected]
CC#224513: Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (PanNEN)
Contact: Paige Steiding (415) 514-6314: [email protected]
CC#22871: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Contact: Lea Daran (415) 353-7912: [email protected]
For information on Early Phase clinical trials not listed please contact: Erika Zigman (415) 353-7381: [email protected]
For information on Immunotherapy trials not listed please contact: Andrew Chon (415) 476-2351: [email protected]